SGK2 and cancer: Being SGK2 a druggable kinase, amplified in a subset of EOC, for which inhibitors are already available our findings could have also an immediate translational relevance to improve the treatment and/or the quality of life of patients with PT-treatable, SGK2-expressing cancers.